Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent ...

The FTC called out the nation’s leading pharmacy benefit managers for inflating pharmacy costs, affecting both employers and ...

The Federal Trade Commission has released its second report digging into how the business practices of pharmacy benefit managers could be inflating drug costs in the U.S., in the latest and likely ...

A new FTC report found that pharmacy benefit managers have inflated the price of life-saving generic prescription drugs, ...

A new FTC report found that pharmacy benefit managers have inflated the price of life-saving generic prescription drugs, finding the companies sometimes increased prices of these drugs by 1,000 ...

A yearslong Federal Trade Commission probe, resulting in a report released in July, reported that of the six pharmacy benefit ...

Pharmacy benefit managers are the middlemen in ... Multiple current FTC commissioners have labeled the interim report and process as flawed.” ...

Pharmacy benefit managers are the middlemen in the prescription drug market. The Federal Trade Commission reports the revenue of four PBMs exceeds $1 trillion and they control 86% of the market.

The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission (FTC) released its second interim staff report on prescription drug middlemen.

The Federal Trade Commission published a second interim staff report on the prescription drug middleman industry, which focuses on pharmacy benefit managers’ influence over specialty generic ...